ARES three-lens brief
Evidence-based stock research on ARES. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · P/E of 113 — priced for high growth; little margin of safety.
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 19.1pp over 30 days.
- P/E of 113 — priced for high growth; little margin of safety.
- Reported earnings on 2026-10-29.
ARES closed at $137.89 (-1.09%) as of 2026-11-12. Market cap: $45.77B. P/E (trailing) 113.0. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 19.1pp over 30 days.. Concerns: p/E of 113 — priced for high growth; little margin of safety.. Last quarter: Revenue $1.23B, net income $302.51M.
Why three lenses on ARES, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ARES across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/ARES" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ARES brief"></iframe>